Charles Schwab Investment Management Inc. raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 10.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,667,271 shares of the biopharmaceutical company's stock after purchasing an additional 242,672 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.89% of Amicus Therapeutics worth $28,486,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. purchased a new stake in Amicus Therapeutics in the second quarter valued at approximately $8,386,000. M&G Plc raised its position in Amicus Therapeutics by 12.4% in the second quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company's stock valued at $7,485,000 after purchasing an additional 82,728 shares during the period. Fiera Capital Corp grew its stake in shares of Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company's stock worth $52,382,000 after acquiring an additional 58,113 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Amicus Therapeutics by 51.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company's stock worth $2,381,000 after acquiring an additional 75,807 shares during the period. Finally, Mutual of America Capital Management LLC raised its stake in shares of Amicus Therapeutics by 24.2% in the second quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company's stock valued at $2,483,000 after acquiring an additional 48,802 shares in the last quarter.
Insider Buying and Selling at Amicus Therapeutics
In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $10,161,054.84. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 30,401 shares of company stock worth $339,363 over the last 90 days. Corporate insiders own 2.20% of the company's stock.
Wall Street Analyst Weigh In
FOLD has been the topic of several recent research reports. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They issued a "buy" rating and a $18.00 target price on the stock. Cantor Fitzgerald boosted their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Morgan Stanley decreased their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Finally, StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $17.63.
Check Out Our Latest Analysis on Amicus Therapeutics
Amicus Therapeutics Stock Performance
NASDAQ FOLD traded down $0.10 during trading hours on Thursday, hitting $9.76. The company had a trading volume of 1,730,874 shares, compared to its average volume of 2,680,316. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57. The company has a market cap of $2.92 billion, a PE ratio of -29.00 and a beta of 0.60. The business has a 50 day moving average of $10.63 and a 200-day moving average of $10.60.
About Amicus Therapeutics
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Articles
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
